Founded in 2008 as a spin-off from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys today is an established leader in next-generation proteomics. From our global headquarters just outside of Zurich, we operate one of the largest proteomics facilities worldwide and make the most advanced proteomics solutions available to life science researchers across industry and academia.
The decoding of the proteome is revolutionizing precision medicine. Deep, multi-dimensional insights on protein expression, function, and structure at large scale, will enable breakthrough discoveries that bring life science to a new level.
We provide access to the proteome by inventing and developing cutting-edge proteomics technology and solutions, and make them widely available to life science researchers and proteomics experts.
Biognosys’ patented next generation proteomics technology utilizes high-resolution mass spectrometry to quantify proteins with high precision and depth. Our proprietary solutions equip researchers from all fields with a multi-dimensional view of protein expression, function, and structure in all major sample types – cells, tissues, or body fluids – across human and non-human species. Through advanced data analytics, we translate data into actionable insights for R&D and clinical research.
Biognosys is the leading inventor and developer of mass spectrometry-based proteomics solutions. With market leading proteome coverage and sample throughput we enable simultaneous quantification of thousands of proteins across thousands of samples.
We offer a versatile portfolio of next-generation proteomics services, software, and kits, coupled with a strong customer experience, tailored to your needs.
With employees based across Switzerland, Europe, and US, and an extensive network of collaborators and distributors, Biognosys supports a global customer base across industry and academia.